Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MacKay Group Chairman James MacKay On Pursuing A “Starbucks” Model For Diagnostics In China: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Armed with a stable of non-invasive diagnostic technologies, the MacKay Group plans to capitalize on the growing need across Asia for inexpensive diagnostic equipment. Last month, the company acquired new cervical cancer diagnostic products through its Biofield unit to complement its own breast cancer diagnostic products, which sell for less than $20,000 (PharmAsia News, Feb. 12, 2009). MacKay Group Chairman James MacKay spoke to PharmAsia News' Hong Kong bureau to outline his vision for a "Starbucks approach" to health care, one in which cancer screenings go alongside facials and manicures at a nearby beauty salon. That reality, he says, is just around the corner.

Table

View full table

Tags:
Latest Headlines

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

Analysis: Novo And Lilly Make Their Money Work

See All
UsernamePublicRestriction

Register

SC071082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By